- Home
- STNG vs KNSA Comparison
STNG vs KNSA Comparison
Compare STNG & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STNG
- KNSA
- Stock Information
- Founded
- STNG 2009
- KNSA 2015
- Country
- STNG Monaco
- KNSA United Kingdom
- Employees
- STNG N/A
- KNSA N/A
- Industry
- STNG Marine Transportation
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- STNG Consumer Discretionary
- KNSA Health Care
- Exchange
- STNG Nasdaq
- KNSA Nasdaq
- Market Cap
- STNG 2.3B
- KNSA 1.9B
- IPO Year
- STNG 2010
- KNSA 2018
- Fundamental
- Price
- STNG $39.76
- KNSA $27.36
- Analyst Decision
- STNG Buy
- KNSA Strong Buy
- Analyst Count
- STNG 4
- KNSA 5
- Target Price
- STNG $60.50
- KNSA $38.80
- AVG Volume (30 Days)
- STNG 740.6K
- KNSA 474.9K
- Earning Date
- STNG 07-29-2025
- KNSA 07-22-2025
- Dividend Yield
- STNG 4.03%
- KNSA N/A
- EPS Growth
- STNG N/A
- KNSA N/A
- EPS
- STNG 10.31
- KNSA N/A
- Revenue
- STNG $1,066,599,000.00
- KNSA $481,166,000.00
- Revenue This Year
- STNG N/A
- KNSA $37.21
- Revenue Next Year
- STNG $1.97
- KNSA $5.32
- P/E Ratio
- STNG $3.86
- KNSA N/A
- Revenue Growth
- STNG N/A
- KNSA 59.45
- 52 Week Low
- STNG $30.63
- KNSA $17.38
- 52 Week High
- STNG $84.67
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- STNG 49.72
- KNSA 62.48
- Support Level
- STNG $39.30
- KNSA $26.28
- Resistance Level
- STNG $41.08
- KNSA $27.90
- Average True Range (ATR)
- STNG 1.03
- KNSA 0.99
- MACD
- STNG -0.30
- KNSA -0.07
- Stochastic Oscillator
- STNG 20.31
- KNSA 82.30
About STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owns, lease finances or bareboat charters in hundred ten product tankers namely thirty nine LR2 tankers, fifty seven MR tankers and forteeen Handymax tankers. The company's fleet of tankers is the largest, most eco-friendly and newest fleet on the water hauling clean petroleum products. They provide seaborne transportation of crude oil and refined petroleum products worldwide. The company generates majority of its revenue from MR vessel.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.